Treatment for a subchondral fracture in the knee ranges from simple activity modification and protected weight bearing to joint replacement surgery, depending on the size of the fracture, how much the joint surface has collapsed, and whether the surrounding cartilage and meniscus are damaged. Most small fractures are managed conservatively at first, with restricted weight bearing and sometimes medication. Larger or progressive lesions that threaten the joint surface often need a procedural intervention, and the options have expanded considerably in recent years.
What a Subchondral Fracture Actually Is
The subchondral bone sits just beneath the cartilage that lines your knee joint. It acts as a shock absorber, distributing mechanical load across the joint surface. A subchondral fracture is a break in that thin plate of bone, often so small it does not show up on a regular X-ray. The fracture triggers a cascade of bone remodeling: increased blood vessel growth, accelerated bone turnover, and swelling in the marrow, all of which can weaken the bone further and damage the cartilage above it.
These fractures typically occur in one of two ways. In younger, active people they can result from repetitive impact or acute trauma. In older adults, they tend to arise from normal daily loading on bone that has already been weakened by osteoporosis or other metabolic changes. When the bone simply cannot withstand ordinary forces, clinicians call it a subchondral insufficiency fracture of the knee, or SIFK.
The Naming Problem That Affects Your Care
For decades, the sudden onset of knee pain with bone marrow edema on MRI was labeled “spontaneous osteonecrosis of the knee,” or SPONK, implying that the bone tissue was dying from loss of blood supply. That label shaped treatment decisions. But histological studies have consistently found something different: when researchers examine the actual bone tissue, they see microfractures, callus formation, and active remodeling rather than dead bone. This has led to a push to reclassify many cases previously called osteonecrosis as subchondral insufficiency fractures instead.
The distinction matters because treatments for bone death (osteonecrosis) and treatments for a stress fracture with active healing potential are not the same. A fracture with viable bone around it has a realistic chance of healing with conservative management, while true avascular necrosis may not. If your clinician still uses the term SPONK, it is worth understanding that the condition may actually be a subchondral insufficiency fracture, which changes the treatment conversation.
How the Fracture Is Diagnosed
MRI is the primary diagnostic tool. Standard X-rays often miss subchondral fractures entirely, especially in the early stages. On MRI, the hallmark findings are a zone of bone marrow edema, which shows up as a bright signal on fluid-sensitive sequences, and sometimes a low-signal fracture line running through the subchondral plate. As the condition progresses, imaging may show flattening or collapse of the joint surface, which is a red flag for worsening outcomes.
Two imaging features carry particular prognostic weight. A large lesion size and the presence of any osteochondral collapse are both associated with a higher risk of the fracture progressing to arthritis and eventually needing surgery. Clinicians also look carefully at the meniscus during the MRI workup. In a study of 253 patients with subchondral insufficiency fractures, roughly three-quarters had a medial meniscus tear, and about 70% specifically had a posterior root or radial tear of the medial meniscus. Those root tears cause the meniscus to extrude outward, removing its cushioning effect and concentrating mechanical stress on the subchondral bone. Finding and addressing a meniscal root tear is often a critical part of the treatment plan.
Conservative Management
The first-line treatment for most subchondral insufficiency fractures is non-surgical. The goal is straightforward: reduce the mechanical load on the damaged bone long enough for it to heal, and manage pain in the meantime.
- Protected weight bearing: Partial or non-weight bearing with crutches or a walker is the cornerstone of conservative treatment. One case report documented fracture resolution on follow-up MRI after roughly four and a half months of a restricted weight-bearing regimen. The duration varies widely depending on the size of the lesion, the patient’s bone health, and how quickly symptoms improve.
- Unloader bracing: For fractures on one side of the knee, an offloading brace can shift mechanical stress to the healthier compartment. This is especially useful for medial compartment fractures, which are the most common location.
- Activity modification: Avoiding high-impact activities, prolonged standing, and stairs reduces repetitive loading on the healing bone.
Recovery under conservative management can be slow. In one published case, a patient required partial weight bearing on crutches for 14 months, received viscosupplementation at 4 months and bone-building medication at 7 months, and still had mild residual pain at 26 months. That case was on the extreme end, but it illustrates that these fractures do not heal on the timeline of a typical broken bone. Patience and realistic expectations are important.
Medications That Can Help
Two classes of drugs have accumulated the most evidence for subchondral insufficiency fractures: bisphosphonates and prostaglandin analogues.
Bisphosphonates are medications originally developed for osteoporosis. They work by slowing bone breakdown, which in the context of a subchondral fracture helps stabilize the damaged area and gives the repair process a chance to catch up. Across multiple studies, bisphosphonates have been reported to reduce the size of the subchondral lesion on MRI, reduce pain, and improve patient-reported knee function. The mechanism is not entirely settled, but the prevailing idea is that by tamping down the excessive bone resorption that follows the initial fracture, bisphosphonates prevent the lesion from enlarging and collapsing.
Iloprost, a synthetic prostaglandin given intravenously, has also shown positive results. Studies have found that iloprost reduces lesion size and pain, and some evidence suggests it may accelerate healing faster than bisphosphonates or simple pain medication alone. It tends to be used more commonly in Europe and is less widely available elsewhere. Teriparatide, a bone-building drug that works through a different pathway, has also been used in individual cases to stimulate bone formation at the fracture site, though the evidence base is thinner.
Subchondroplasty and Calcium Phosphate Injection
When conservative treatment is not enough, or when the bone marrow lesion is large and painful, a minimally invasive procedure called subchondroplasty has become an increasingly popular option. The technique involves injecting a calcium phosphate bone substitute directly into the area of damaged subchondral bone under fluoroscopic guidance. The material fills the void left by the fracture and the surrounding edema, provides structural support, and is gradually replaced by the patient’s own bone over time.
A prospective multicenter study found that patients who received calcium phosphate injection for bone marrow lesions in mild to moderate knee osteoarthritis had substantial pain improvement at two years, with pain scores roughly doubling from baseline. Surgery-free survivorship was about 92% at two years, meaning that fewer than 1 in 10 patients needed a reoperation during that period. Another study of 164 patients found that the large majority recovered with significant functional improvement, though about a quarter still had some residual pain. Return to normal activities occurred at around three months on average.
When compared head-to-head with knee arthroscopy alone, calcium phosphate injection combined with arthroscopy produced greater functional improvement than arthroscopy by itself. This suggests the bone-level problem needs to be addressed directly, not just the cartilage or meniscal issues visible inside the joint.
Osteochondral Grafting for Larger Defects
When the joint surface has already collapsed or the defect is too large for simpler procedures, reconstructive surgery using osteochondral grafts enters the picture. There are two main approaches: autograft transplantation, which uses bone and cartilage plugs harvested from a non-weight-bearing area of the patient’s own knee, and allograft transplantation, which uses donor tissue from a cadaver.
Osteochondral autograft transplantation has shown favorable long-term results for subchondral insufficiency fractures specifically. In one series of 33 procedures with a mean follow-up exceeding 13 years, the 15-year survival rate of the graft was 88%, meaning that only one patient in the group required conversion to a joint replacement over that entire period. Functional scores improved substantially, and about four in five patients were considered clinical successes. In nearly half the cases, surgeons also performed a high tibial osteotomy at the same time to correct leg alignment and redistribute weight away from the damaged compartment.
Osteochondral allograft transplantation is typically reserved for larger defects where autograft would require harvesting too much of the patient’s own tissue. It offers the advantage of replacing both the damaged cartilage and the underlying bone in a single procedure with mature hyaline cartilage. One study reported allograft survivorship of about 83% at five years and 70% at ten years, with the caveat that the reoperation rate was high. Among patients whose grafts survived, the large majority reported satisfaction with the outcome.
When Joint Replacement Becomes Necessary
For patients whose subchondral fractures progress to significant joint collapse or advanced arthritis despite other treatments, joint replacement is the final option. The choice between a partial knee replacement, known as unicompartmental knee arthroplasty, and a total knee replacement depends on whether the damage is confined to one compartment or has spread more widely.
Both procedures produce meaningful improvements in pain and function for patients with subchondral insufficiency fractures. A comparative study found that unicompartmental and total knee arthroplasty both led to significant gains in clinical scores at final follow-up. Unicompartmental arthroplasty preserves more of the native joint and tends to allow faster recovery, but carries a somewhat higher relative risk of complications, though the difference was not statistically significant in that study. The key is proper patient selection: if the disease is truly limited to one side of the knee, a partial replacement can be an excellent solution, as illustrated by case reports showing complete pain resolution at one year.
Conversion rates to total knee replacement after other procedures provide some context for how often these fractures ultimately end up at this stage. Reported rates range from about 8% at roughly 15 months of follow-up to 30% at two years, depending on the severity of the initial injury and the degree of pre-existing arthritis.
The Meniscus Connection
A damaged meniscus is not just a bystander in subchondral insufficiency fractures. Research has established a tight link between medial meniscus posterior root tears and the development of these fractures. In a large study, over 80% of patients with a subchondral insufficiency fracture on the medial femoral condyle had a medial meniscus tear, and about 87% of those with a fracture on the medial tibial plateau did as well. Over 90% of the posterior root and radial tears in that study were associated with meniscal extrusion of 3 millimeters or more.
The meniscus normally acts as a load-distributing washer in the knee. When a root tear allows it to extrude, it stops doing that job, and the subchondral bone beneath takes the full brunt of each step. This is why treating a subchondral fracture in isolation, without addressing the underlying meniscal pathology, often leads to disappointing results. Surgeons may repair the meniscal root tear either alongside conservative management of the fracture or as part of a larger surgical plan. However, a study tracking patients who had meniscal root repair found that those who also had a preoperative subchondral insufficiency fracture were more likely to show arthritis progression afterward, suggesting the fracture itself carries its own risk even when the meniscus is addressed.
Osteoporosis and Bone Quality as Treatment Drivers
Because subchondral insufficiency fractures often occur in bone that is already weakened, addressing the underlying bone health is a parallel treatment priority. Research has highlighted a relationship between osteoporosis and subchondral insufficiency fractures, with some investigators proposing that certain cases represent a distinct subtype of osteoarthritis driven by osteoporotic subchondral bone damage.
In practical terms, this means your doctor should be evaluating your bone density if you develop a subchondral insufficiency fracture, especially if you are postmenopausal, over 60, or have other risk factors for thin bones. If osteoporosis is present, treating it with appropriate medication is not just good general practice; it directly supports healing at the fracture site by improving the quality of the bone that needs to repair itself. This is one reason bisphosphonates serve double duty in these patients, treating both the local fracture and the systemic bone loss that contributed to it.
Emerging Approaches
Extracorporeal shock wave therapy, a technique already used for conditions like plantar fasciitis and tennis elbow, is being investigated for its effects on subchondral bone and cartilage. In animal studies, shock wave treatment significantly improved subchondral bone quality, restoring bone mineral density and trabecular structure toward normal levels. Functional measures like gait also normalized over several weeks. The treatment appears to promote bone remodeling in a way that favors repair rather than continued deterioration.
Human clinical data on shock wave therapy for subchondral knee fractures specifically remain limited, and the technique is not yet a standard recommendation. But it represents the direction research is heading: toward treatments that can stimulate the bone’s own repair capacity rather than simply replacing the damaged tissue. Platelet-rich plasma injections and other biologic therapies are also being explored in this space, though the evidence remains early-stage for subchondral fractures specifically.
How Treatment Decisions Are Actually Made
If you are facing a subchondral fracture diagnosis, the treatment path usually follows a loose algorithm based on a few key variables. The size of the lesion on MRI is the single biggest driver. Small lesions with no evidence of surface collapse get a trial of conservative management, typically for three to six months. The presence or absence of a meniscal root tear influences whether a concurrent procedure is needed. Your bone density and metabolic health determine whether medication is added. And whether the joint surface has already flattened or collapsed separates the patients who can wait from those who need earlier intervention.
Age also plays a role, though not always in the direction you might expect. Younger patients with acute traumatic fractures may heal faster but face a longer timeline of needing the joint to last. Older patients with insufficiency fractures may have slower bone healing but are closer to an age where joint replacement, if needed, offers a durable lifetime solution. The treatment plan for a 45-year-old athlete and a 72-year-old with osteoporosis look quite different even if the MRI findings are similar.
One common misconception is that a subchondral fracture automatically means surgery. Most do not. But ignoring the injury or pushing through pain without modifying activity risks turning a fracture that could heal into one that collapses, and a collapsed joint surface is much harder to salvage. Early diagnosis via MRI and a structured treatment plan give the fracture the best chance of resolving without a major procedure.